Teuber, Gerlinde

Publishing since 1993 (Senior)

Has published 44 publications in 18 years

Number of publications published per year by Teuber, Gerlinde. (Source : PubMed)

Distribution of publications types for Teuber, Gerlinde. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Teuber G, Wollschlaeger S, Baumgarten A, Simon KG, Moog G, Dikopoulos N, Mauss S. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study.  J. Viral Hepat.  2010  
•  Berger A, Giroglou T, Leutz A, Ogbomo H, Pfaff K, Teuber G, Cinatl J, van Laer D, Doerr HW. Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp).  J. Clin. Virol.  2009;46;1  
•  Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Balk H, Zankel M, Neumann K, Sarrazin C, Zeuzem S. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.  Hepatology  2009;50;2  
•  Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.  Ann. Intern. Med.  2009;150;8  
•  Teuber G, Schäfer A, Rimpel J, Paul K, Keicher C, Scheurlen M, Zeuzem S, Kraus MR. Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis.  J. Hepatol.  2008;49;6  
•  von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.  Hepatology  2008;48;5  
•  Halangk J, Sarrazin C, Neumann K, Puhl G, Mueller T, Teuber G, Klinker H, Hinrichsen H, Buggisch P, Landt O, Weich V, Bergk A, Wiedenmann B, Neuhaus P, Berg T, Witt H. Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.  J. Hepatol.  2008;49;3  
•  Trojan J, Stuermer M, Teuber G, Berger A, Faust D. Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?  Gut  2007;56;3  
•  von Wagner M, Lee JH, Kronenberger B, Friedl R, Sarrazin C, Teuber G, Herrmann E, Zeuzem S. Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels.  J. Viral Hepat.  2006;13;12  
•  Hoepffner N, Paul KA, Nikodem AB, Teuber G. [High dose repeat therapy in previously treated patients with chronic hepatitis C]  Dtsch. Med. Wochenschr.  2006;131;11  

[ See timeline ] [ See all publications ]